New combo therapy shows promise for aggressive breast cancer

NCT ID NCT03368729

Ongoing Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of two drugs—niraparib and trastuzumab—in people with metastatic HER2-positive breast cancer, an aggressive form of the disease. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth. About 46 women with advanced cancer that has spread will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CARCINOMA METASTATIC BREAST CANCER

Contacts and locations

Locations

Mayo Clinic

Rochester, Minnesota, 55905, United States
Montefiore

The Bronx, New York, 10461, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of North Carolina

Chapel Hill, North Carolina, 27599, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Washington-

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.